Retatrutide
Symbol Rt · MW 4731 Da
Triple-agonist peptide showing record weight-loss results in trials.
- Discovered
- 2022
- Half-life
- 6 days
- Approval
- Investigational
Quick facts
- Category
- Weight Loss
- Route
- Injectable
- Molecular weight
- 4731 Da
- Half-life
- 6 days
- Discovered
- 2022
- Approval status
- Investigational
Reported effects
- Major weight loss
- Improved metabolism
- Lipid effects
Overview
Retatrutide is an investigational weight loss peptide known as a triple agonist because it targets GLP-1, GIP, and glucagon receptors. These three metabolic hormone pathways are involved in appetite regulation, insulin response, blood sugar control, and energy balance. Retatrutide is being studied for obesity, weight management, and metabolic health because it may combine appetite suppression with broader effects on energy expenditure and glucose metabolism. Unlike single-pathway GLP-1 peptides, Retatrutide is designed to influence multiple systems at the same time. It is considered one of the more advanced next-generation metabolic peptides, though it remains investigational and should not be treated as a standard approved weight loss medication.
Evidence context
Retatrutide evidence summary
Human clinical evidence
Human clinical evidence for Retatrutide may be limited, investigational, region-specific, or unavailable in the local source data. Peptidic avoids treating reported effects as proven clinical outcomes.
Animal, preclinical, or formulation evidence
Retatrutide may be discussed in animal, preclinical, in vitro, or early-stage research contexts. Those evidence types are useful for orientation but should not be treated as equivalent to approved human indications.
Status and evidence strength
Peptidic lists the approval status for Retatrutide as Investigational. The reported effects below are reference fields from the peptide database, not medical promises. Source links are included later on the page when available so readers can continue review from primary or reputable sources.
How it's taken
- Typical Administration
- Injectable
- Typical Dosage
- Investigational research range: 1–12 mg
- Typical Frequency
- Once weekly
There is no established FDA-approved dosage for this peptide. This information is for educational reference only and should not be treated as medical guidance.
Research sources
Source links included from peer-reviewed literature, clinical records, and medical databases for educational research context on Retatrutide.
Internal links
Related peptides
Frequently asked questions
What category is Retatrutide in?
Retatrutide is listed in the Weight Loss category on Peptidic.
What route is Retatrutide associated with?
Retatrutide is associated with the injectable route in the Peptidic database. This is descriptive route context, not a use instruction.
Is Retatrutide approved?
Peptidic lists the approval status for Retatrutide as: Investigational. Approval details can vary by indication and jurisdiction.
Interested in Retatrutide?
Enter your email and we'll send our recommended peptide vendor for educational research reference.
Review the peptide vendor research checklistEducational reference only · No spam · Unsubscribe anytime
For educational purposes only. Many peptides shown are research compounds and not approved for human use in all jurisdictions. Explore the full peptide database, peptide calculator, or peptide tracker.
Last reviewed for educational accuracy: 2026-06-01